IBM and Illumina Partner on Work to Standardize Genomic Data Interpretation | Healthcare Informatics Magazine | Health IT | Information Technology Skip to content Skip to navigation

IBM and Illumina Partner on Work to Standardize Genomic Data Interpretation

January 10, 2017
by Heather Landi
| Reprints

IBM Watson Health and Illumina, Inc., a DNA sequencing and array-based technologies company, are partnering with the aim of helping cancer genomics researchers interpret the results of sequences.

As part of the partnership, IBM will integrate Watson for Genomics into Illumina’s BaseSpace Sequence Hub and tumor sequencing process. The collaboration is designed to help standardize and simplify genomic data interpretation. Genome sequencing has increased in recent years following two decades of research demonstrating the promise of precision medicine. However, access to these advances has been limited by the significant time and expense required to interpret the genomic data.

According to an IBM press release, by adding Watson for Genomics to Illumina’s next-generation sequencing platform, researchers who use Illumina’s cancer genome sequencing panel will have rapid access to information to help interpret the broad array of variant data produced by TruSight Tumor 170.  Illumina’s TruSight Tumor 170 is a solid tumor profiling panel designed to detect a comprehensive set of variants across 170 genes.

Through the technology integration, Watson for Genomics will read the genetic alteration files produced by TruSight Tumor 170, comb professional guidelines, medical literature, clinical trials compendia, and other sources of knowledge to provide information for each genomic alteration, and produce a report for use by researchers—a process that typically takes scientists more than one week to complete. Watson for Genomics ingests data from approximately 10,000 scientific articles and 100 new clinical trials every month.

The Watson for Genomics software will be available to support Illumina’s TruSight Tumor 170 assay early in 2017. The Watson service is not yet available for diagnostic use and is for research use only.

 

 

Get the latest information on Health IT and attend other valuable sessions at this two-day Summit providing healthcare leaders with educational content, insightful debate and dialogue on the future of healthcare and technology.

Learn More

Topics

News

AHRQ Launches App Challenge for PRO Data Standardization

The Agency for Healthcare Research and Quality (AHRQ) has launched a competition to address the need for greater use of standardized patient-reported outcomes (PRO) data in clinical care and research.

Study: Many U.S. Hospitals won’t Reach HIMSS Stage 7 Until 2035

Unless the healthcare IT ecosystem experiences major policy changes or leaps in technological capabilities, many hospitals will not reach Stage 7 of HIMSS Analytics’ Electronic Medical Record Adoption Model until 2035, according to new research.

Amazon, Google, IBM and Other Tech Giants Pledge to Remove Barriers to Interoperability

Six of the world's biggest technology companies, including Microsoft, Google, IBM and Amazon, made a joint pledge at the White House Monday to remove interoperability barriers and to make progress on adoption of health data standards.

Mayo Clinic Elects New President and CEO

Gianrico Farrugia, M.D., current vice president, Mayo Clinic, and CEO of Mayo Clinic in Florida has been elected as the president and CEO of the Mayo Clinic, headquartered in Minnesota.

Fitbit, Blue Cross Blue Shield Launch Mobile Health Partnership

San Francisco-based fitness wearable maker Fitbit continues its push into the health plan market with a new digital health deal to incorporate its fitness tracker into health and wellness programs.

ASCO Picks IBM Watson Exec to Lead CancerLinQ

The American Society of Clinical Oncology (ASCO) has named a former IBM Watson executive as the new CEO of its CancerLinQ big data platform.